Novartis Valuation
Is NOVNEE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOVNEE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NOVNEE (CHF91.06) is trading below our estimate of fair value (CHF263.97)
Significantly Below Fair Value: NOVNEE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOVNEE?
Key metric: As NOVNEE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NOVNEE's PE Ratio? | |
|---|---|
| PE Ratio | 17.5x |
| Earnings | US$11.76b |
| Market Cap | US$206.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 10.7x |
| PEG Ratio | 2.5x |
Price to Earnings Ratio vs Peers
How does NOVNEE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.5x | ||
ROG Roche Holding | 18.8x | 11.1% | CHF 201.3b |
DESN Dottikon ES Holding | 39.2x | n/a | CHF 3.2b |
COPN Cosmo Pharmaceuticals | 15.4x | 17.2% | CHF 1.0b |
LONN Lonza Group | 64.7x | 23.9% | CHF 37.1b |
NOVNEE Novartis | 17.5x | 7.0% | CHF 182.1b |
Price-To-Earnings vs Peers: NOVNEE is good value based on its Price-To-Earnings Ratio (17.5x) compared to the peer average (34.5x).
Price to Earnings Ratio vs Industry
How does NOVNEE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: NOVNEE is good value based on its Price-To-Earnings Ratio (17.5x) compared to the European Pharmaceuticals industry average (20.6x).
Price to Earnings Ratio vs Fair Ratio
What is NOVNEE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17.5x |
| Fair PE Ratio | 28.3x |
Price-To-Earnings vs Fair Ratio: NOVNEE is good value based on its Price-To-Earnings Ratio (17.5x) compared to the estimated Fair Price-To-Earnings Ratio (28.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Roche Holding
CHF 201.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
RO
CHF 266.20
7D
-5.8%
1Y
5.7%
Roche Holding
CHF 201.3b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
ROG
CHF 250.50
7D
-4.6%
1Y
5.4%
Bristol-Myers Squibb
US$100.3b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$54.24
7D
0%
1Y
0%